Comparing overall survival of patients with metastatic uveal melanoma by sequence of Tebentafusp versus combination immune checkpoint inhibitors.

被引：0
|
作者：
Shikdar, Sufana
Day, Silas
Ikeguchi, Alexandra
Ying, Yuan
机构：
[1] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA
[2] Univ Oklahoma, Med Ctr, Oklahoma City, OK USA
[3] Stephenson Canc Ctr, Oklahoma City, OK USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21505
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Similar overall survival in tebentafusp-treated 2L+metastatic uveal melanoma regardless of prior immunotherapy
    Piulats, J. M.
    Sato, T.
    Luke, J. J.
    Collins, L.
    Edukulla, R.
    Abdullah, S. E.
    Leyvraz, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S854 - S854
  • [22] A propensity score weighted comparison of tebentafusp or pembrolizumab versus combination ipilimumab and nivolumab in untreated metastatic uveal melanoma
    Piulats Rodriguez, J. M.
    Piperno-Neumann, S.
    Rutkowski, P.
    Nathan, P.
    Hassel, J. C.
    Espinosa, E.
    De la Cruz Merino, L.
    Ochsenreither, S.
    Shoushtari, A. N.
    Orloff, M.
    Salama, A. K. S.
    Watkins, C.
    Goodall, H.
    Baurain, J-F.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S924 - S924
  • [23] Impact of clinicopathological characteristics on survival in patients treated with immune checkpoint inhibitors for metastatic melanoma
    Zhao, Bin
    Zhao, Hong
    Zhao, Jiaxin
    INTERNATIONAL JOURNAL OF CANCER, 2019, 144 (01) : 169 - 177
  • [24] Immune checkpoint inhibitors in a cohort of 206 metastatic uveal melanomas patients
    Saint-Ghislain, M.
    Geoffrois, L.
    Gastaud, L.
    Lesimple, T.
    Negrier, S.
    Penel, N.
    Kurtz, J-E.
    Le Corre, Y.
    Gardrat, S.
    Barnhill, R.
    Cassoux, N.
    Mariani, P.
    Servois, V.
    Piperno-Neumann, S.
    Rodrigues, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [25] OVERALL SURVIVAL ON TEBENTAFUSP IN METASTATIC UVEAL MELANOMA (MUM) ACROSS THE RANGE OF TUMOR GP100 EXPRESSION LEVELS
    Leach, Emma
    Stanhope, Sarah
    Naidoo, Revashnee
    Abdullah, Shaad
    Collins, Laura
    Ranade, Koustubh
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A909 - A909
  • [26] Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitors
    Sander, Michael
    Stukalin, Igor
    Vallerand, Isabelle A.
    Goutam, Siddhartha
    Ewanchuk, Benjamin W.
    Meyers, Daniel E.
    Pabani, Aliyah
    Morris, Don
    Heng, Daniel Y. C.
    Cheng, Tina
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB170 - AB170
  • [27] Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitors
    Sander, Michael S.
    Stukalin, Igor
    Vallerand, Isabelle A.
    Goutam, Siddhartha
    Ewanchuk, Benjamin W.
    Meyers, Daniel E.
    Pabani, Aliyah
    Morris, Don G.
    Heng, Daniel Y. C.
    Cheng, Tina
    CANCER MEDICINE, 2021, 10 (08): : 2618 - 2626
  • [28] Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis
    Piulats, J. M.
    Watkins, C.
    Costa-Garcia, M.
    del Carpio, L.
    Piperno-Neumann, S.
    Rutkowski, P.
    Hassel, J. C.
    Espinosa, E.
    de la Cruz-Merino, L.
    Ochsenreither, S.
    Shoushtari, A. N.
    Orloff, M.
    Salama, A. K. S.
    Goodall, H. M.
    Baurain, J. -F.
    Nathan, P.
    ANNALS OF ONCOLOGY, 2024, 35 (03) : 317 - 326
  • [29] Effect of subsequent therapies including checkpoint inhibitors on overall survival in a phase III randomized trial of tebentafusp in first-line metastatic uveal melanoma: Long-term follow-up
    Orloff, M.
    Watkins, C.
    Carvajal, R. D.
    Shoushtari, A. N.
    Sacco, J. J.
    Schlaak, M.
    Gama, J.
    Butler, M. O.
    ANNALS OF ONCOLOGY, 2023, 34 : S678 - S678
  • [30] Early ctDNA reduction is associated with better overall survival in the Ph 3 trial of tebentafusp in previously untreated metastatic uveal melanoma
    Sullivan, Ryan
    Collins, Laura
    Rodrigues, Manuel
    Nathan, Paul
    Hassel, Jessica C.
    Dummer, Reinhard
    Kirkwood, John
    Rutkowski, Piotr
    Baurain, Jean-Francois
    Butler, Marcus O.
    Schlaak, Max
    Ochsenreither, Sebastian
    Abdullah, Shaad E.
    Holland, Chris
    Ranade, Koustubh
    Shoushtari, Alexander N.
    CANCER RESEARCH, 2023, 83 (07)
12345